Latest news with #Centauri
Yahoo
2 days ago
- Business
- Yahoo
Centauri Insurance and Lilypad Insurance Sponsor $30 Million Koi Re Private Catastrophe Bond
SARASOTA, Fla., June 4, 2025 /PRNewswire/ -- Centauri Insurance and Lilypad Insurance announced today the successful issuance of Koi Re, a $30 million catastrophe bond designed to provide indemnity- based reinsurance protection against named storms in the United States. This strategic initiative marks a significant step in leveraging the capital markets to enhance the companies' risk management strategies. The Koi Re transaction provides one year of coverage, enabling Centauri and Lilypad to transfer a portion of their named storm risk to the capital markets. This privately-placed, 4(a)(2) issuance enables the companies to diversify their risk transfer tools and secure additional capacity to support policyholders in the event of a significant named storm event. The $30 million tranche of Koi Re Series 2025-1 Class A notes, which were structured and placed by Lockton Re Capital Markets, provide indemnity reinsurance coverage on a per occurrence basis across Lilypad's exposures in Hawaii, Texas, Louisiana, Mississippi, Alabama, Florida, and South Carolina through May 31, 2026. Koi Re was issued via a Segregated Account of Sailfish Re Ltd. ("Sailfish Re"), a Bermuda based Unrestricted Special Purpose Insurer and Segregated Accounts Company, that offers Lockton Re's clients the ability to rapidly access broader pools of capital through an independently-managed, established platform. "The successful placement of Koi Re underscores our commitment to innovative risk management solutions," said Ricardo Espino, CEO of Lilypad Insurance. "By accessing the capital markets via our inaugural catastrophe bond, we have introduced a new capital source to better protect our policyholders and ensure financial resilience against catastrophic events as we continue to grow our operations." Zach Breslin, Head of Lockton Re Capital Markets, added, "We are proud to support Centauri and Lilypad in this important transaction. Koi Re exemplifies how insurers can effectively access the capital markets to manage exposure to natural disasters and is the latest example of Sailfish Re's utility in delivering bespoke funded solutions to address client needs." This transaction reflects a continued evolution in how insurers access alternative capital to strengthen their reinsurance programs and reinforce financial stability in the face of increasing climate-related risks. About Centauri Specialty Insurance Company Formed in 2006 and based in Sarasota, FL, Centauri Specialty Insurance Company is a property and casualty insurance company licensed to serve policyholders in seven states including Alabama, Florida, Hawaii, Louisiana, Mississippi, South Carolina and Texas. Centauri is well known for providing catastrophe coverage and for its ability to provide financial protection to its policyholders, through innovative solutions and personalized service. Visit Centauri online at About Lilypad National Insurance Company Lilypad National Insurance Company delivers specialized insurance solutions to homeowners and property owners in coastal areas. By applying advanced technology and leveraging extensive industry experience, Lilypad Insurance seeks to provide robust coverage options that meet its clients' unique challenges. Visit Lilypad Insurance online at About Lockton Re and Lockton Re Capital Markets Lockton Re, the reinsurance business of Lockton, helps businesses understand, mitigate, and capitalize on risk. With over 500 colleagues in 22 locations globally, the business is continuing to grow, pushing the reinsurance industry forward with smarter solutions that leverage new technologies—delivered by people empowered to do what's right for clients. Securities products and services are offered in the U.S. through Lockton Re Capital Markets, LLC ("LRCM, LLC"), a broker-dealer registered with the U.S. SEC and member of FINRA and SIPC. Securities products and services are offered in the European Economic Area by Lockton Re Capital Markets Limited ("LRCM Ltd") which is authorized and regulated by the Central Bank of Ireland, Company Registration Number 756328. Reinsurance broking and analytical services offered through Lockton Re, LLC ("Lockton Re"). LRCM, LLC and LRCM Ltd (collectively, "LRCM") are affiliates of Lockton Re. For more information, visit View original content to download multimedia: SOURCE Centauri & Lilypad Insurance Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
13-05-2025
- Business
- Yahoo
Florida slaps property insurance company with $100K fine over Hurricane Ian claims
Video above: 'Broke' insurance companies moved money, report finds TAMPA, Fla. (WFLA) — Florida insurance regulators fined a property insurance company $100,000 for its mishandling of claims in the wake of Hurricane Ian in 2022. According to a consent order document provided by the Florida Office of Insurance Regulation, Centauri Specialty Insurance Company failed to utilize properly appointed adjusters and provide a disclosure statement when providing payments on claims that were not the full and final payment. Manatee dies while receiving medical care at Florida state park: report Insurance regulators pointed to 168 instances where the company used insurance adjusters who were not properly appointed. Florida law requires them to be licensed and appointed. The office said that Centauri 'did not provide the particular disclosure statement when providing a payment on a claim that was not the full and final payment in 141 instances.' Centauri was fined $100,000, plus $2,000 in administrative costs. As part of the agreement, the company acknowledged it could face administrative penalties if caught violating the terms of the consent order in the future. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
26-04-2025
- Business
- Yahoo
Centauri Health Solutions acquires health information service provider MedAllies
US-based healthcare IT company Centauri Health Solutions has acquired MedAllies to expand its health data network for supporting 'mission-critical' use cases. MedAllies is a health information service provider (HISP) and qualified health information network (QHIN) focused on data connectivity and exchange. The acquisition adds 'industry-leading' integration, messaging and record location services to Centauri's capabilities, offering access to care and financial assistance for more patients, particularly those who are most vulnerable. MedAllies CEO Dr John Blair said: 'Centauri is the perfect partner for MedAllies. Our shared vision for interoperability and bi-directional exchange is essential to advancing healthcare. 'We are excited to offer our clients the broadest clinical exchange network to support mission-critical use cases.' MedAllies serves a network of more than 1,000 hospitals and health systems, 5,000 ambulatory organisations and 125,000 healthcare providers. The company aims to ensure the secure transmission of critical health information across national networks. Centauri Health Solutions co-founder and CEO Mike McNelis said: 'The addition of MedAllies strengthens our commitment to intelligently deliver clinical data solutions in a manner and form that facilitates value creation and empowers shared risk initiatives. 'Connecting the MedAllies HISP and best-in-class Care Enabled Network/QHIN with Centauri's network and AI solutions offers significant value to all our clients.' The acquisition has been supported by Centauri Health Solutions' lead investor, Abry Partners, as well as Silversmith Capital Partners and SV Health Investors. Santander served as financial adviser to MedAllies while HunterMaclean provided legal counsel to the company. Kirkland and Ellis acted as legal counsel for Centauri. Last year, health and safety IT company Beyond Lucid Technologies selected MedAllies as its QHIN partner. The partnership aimed to enable real-time information sharing within the mobile medicine ecosystem, linking ambulances, hospitals and public health entities. At that time, MedAllies had recently been designated as a QHIN under the US Government's Trusted Exchange Framework and Common Agreement. "Centauri Health Solutions acquires health information service provider MedAllies" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Business Wire
24-04-2025
- Business
- Business Wire
Centauri Health Solutions Acquires MedAllies, Broadens Health Data Network to Support Mission Critical Use Cases
PHOENIX--(BUSINESS WIRE)--Centauri Health Solutions ('Centauri'), a Phoenix, Arizona-based health information technology company, announced its acquisition of MedAllies, a New York-based Health Information Service Provider (HISP) and Qualified Health Information Network® (QHIN™) focused on health data connectivity and clinical data exchange. 'The addition of MedAllies strengthens our commitment to intelligently deliver clinical data solutions in a manner and form that facilitates value creation and empowers shared risk initiatives." - Mike McNelis, Centauri Co-Founder and CEO A trailblazer in healthcare interoperability, MedAllies serves more than 1,000 hospitals/health systems, 5,000 ambulatory organizations, and 125,000 healthcare providers, ensuring the secure and seamless transmission of critical health information through national networks. This acquisition boosts Centauri's solutions with industry-leading integration, messaging, and record location services, enhancing access to care and financial support for patients, especially the most vulnerable. 'Centauri is the perfect partner for MedAllies. Our shared vision for interoperability and bi-directional exchange is essential to advancing healthcare,' said Dr. John Blair, CEO of MedAllies. 'We are excited to offer our clients the broadest clinical exchange network to support mission critical use cases.' Mike McNelis, Centauri co-founder and CEO, added, 'The addition of MedAllies strengthens our commitment to intelligently deliver clinical data solutions in a manner and form that facilitates value creation and empowers shared risk initiatives. Connecting the MedAllies HISP and best-in-class Care Enabled Network/QHIN with Centauri's network and AI solutions offers significant value to all our clients.' The acquisition was supported by Centauri's lead investor, Abry Partners, along with Silversmith Capital Partners and SV Health Investors. Santander served as the financial advisor to MedAllies with HunterMaclean as legal counsel. Kirkland and Ellis was legal counsel to Centauri for the transaction. About Centauri Health Solutions Centauri Health Solutions offers technology-enabled solutions to health systems and health plans for various healthcare programs including Medicare, Medicaid, Commercial and Exchange. Through collaboration with clients, we improve the lives and health outcomes of patients and members through compassionate outreach, sophisticated analytics, and intelligent clinical data delivery. Centauri addresses market issues such as uncompensated care in health systems; risk-adjusted revenue for specialized populations; and enhances access to and quality of care measurement. Headquartered in Phoenix, Arizona, Centauri Health Solutions employs 1,500 associates nationwide. Centauri has been listed on the Inc. 5000 from 2019-2022, and the 2020 Deloitte Technology Fast 500™ list. More details can be found at About Abry Partners Abry Partners is one of the most experienced and successful sector-focused private equity investment firms in North America. Since its founding in 1989, the firm has completed over $90 billion of leveraged transactions and other private equity or preferred equity placements. Currently, the firm manages over $5.0 billion of capital across its active funds. For more information about Abry Partners, visit About Silversmith Capital Partners Founded in 2015, Silversmith Capital Partners is a Boston-based growth equity firm with $3.3 billion of capital under management. Silversmith's mission is to partner with and support the best entrepreneurs in growing, profitable technology and healthcare companies. Representative investments include ActiveCampaign, Appfire, Apryse, DistroKid, Iodine Software, LifeStance Health, Onbe, and Webflow. For more information, including a full list of portfolio investments, visit or follow the firm on LinkedIn. About SV Health Investors SV Health Investors ('SV') is a private equity firm dedicated to investments in the healthcare and life sciences sector. Founded in 1993, with offices in Boston and London, SV manages >$2.0 billion across multiple investment strategies. SV's dedicated healthcare growth-buyout strategy seeks to partner with experienced management teams to accelerate the success of innovative healthcare companies across outsourced services, life sciences and medical products, tech-enabled healthcare services, and healthcare information technology. Over the past 30+ years, SV has invested in 250+ healthcare companies. For more information about SV, visit
Yahoo
04-03-2025
- Business
- Yahoo
Centauri Therapeutics Selects First Clinical Candidate, for Immunotherapeutic Treatment of Gram-negative Bacterial Infections
Lead candidate in the ABX-01 programme to progress into first-in-human clinical studies Programme designed to treat Gram-negative bacterial lung infections in the most vulnerable patients LONDON, March 04, 2025--(BUSINESS WIRE)--Centauri Therapeutics Limited (Centauri), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced the selection of its first clinical candidate in the ABX-01 programme. Based on the Company's Alphamer® platform, the compound is designed to target serious Gram-negative bacterial infections in the lung, expanding therapeutic options for the most vulnerable patients. This drug candidate will now be further developed ahead of progression to first in-human clinical studies. The lead candidate in the ABX-01 programme is a broad-spectrum antimicrobial peptide specifically selected to combat clinically prevalent and multidrug-resistant bacterial strains. It employs a dual mechanism of action, combining immunotherapeutic effects through complement fixation and phagocytosis with intrinsic antibacterial properties, within a single molecule. Preclinical studies have demonstrated the compound's activity against Gram-negative bacteria. "We are excited to enter the clinical development phase with the ABX-01 lead candidate, thanks to our dedicated team who have worked hard to advance our Alphamer platform to this crucial stage. The platform has the potential to address a vital gap in the current anti-infective treatment landscape, and we remain confident that our lead candidate will continue to demonstrate this as we progress towards a Phase I clinical trial," commented Dr Jennifer Schneider, CEO, Centauri Therapeutics. "We are proud to progress this molecule with the continuous support of our investors and our long-standing partner, CARB-X, for which we are grateful." Dr Helen Bright, CSO, Centauri Therapeutics, said: "Our focus at Centauri Therapeutics has always been on developing novel immune therapy approaches to expand treatment options for the most vulnerable, starting with the anti-infectives space. Reaching this stage highlights the potential of our disruptive technology, not only in anti-infectives, but also within the oncology and vaccines spaces. I look forward to working alongside our brilliant and highly motivated team to take us into this next phase of development." Centauri is now conducting regulatory preclinical activities to enable streamlined progression of its lead clinical candidate into a Phase I clinical trial. Research reported in this press release is supported by CARB-X. CARB-X's funding for this project is provided in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842), and Germany's Federal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. View source version on Contacts Katie Sign in to access your portfolio
